Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,151 recruiting studies in this area right now.
By phase
- Not applicable9,506
- Phase 24,400
- Phase 12,662
- Phase 1/Phase 21,649
- Phase 31,391
- Phase 2/Phase 3283
- Phase 4260
Top conditions
- Breast Cancer1,197
- Prostate Cancer647
- Cancer634
- Colorectal Cancer480
- Lung Cancer416
- Ovarian Cancer336
- Multiple Myeloma328
- Pancreatic Cancer288
- Gastric Cancer283
- Acute Myeloid Leukemia279
- Hepatocellular Carcinoma256
- Solid Tumor245
- Advanced Solid Tumor235
- Head and Neck Cancer225
- Cervical Cancer223
- Endometrial Cancer207
- Advanced Solid Tumors201
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University302
- National Cancer Institute (NCI)292
- Memorial Sloan Kettering Cancer Center288
- Sun Yat-sen University273
- Mayo Clinic238
- City of Hope Medical Center141
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences140
- AstraZeneca133
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,408
- Texas635
- Arizona512
- Florida434
- Alabama427
- New York405
- Massachusetts342
- Maryland330
- New Jersey269
- Pennsylvania234
Recruiting studies20,151 total
- NCT07589543RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Ovarian Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight ovarian cancer that has returned or stopped responding to standard treatments. The therapy uses cells from your own body that have been modified in the lab to recognize and attack cancer cells.
Shenzhen, GuangdongAges 18–75 - NCT07589569RecruitingPhase 2
HRS-7058 for Advanced Pancreatic Cancer Treatment
This study tests a new drug called HRS-7058 in patients with pancreatic cancer that has spread or cannot be removed by surgery. You may qualify if your cancer has already been treated with at least one prior therapy and you have measurable disease on imaging.
Nanjing, JiangsuAges 18–75 - NCT07593248Recruiting
Real-World Lung Cancer Outcomes With Targeted Drug Therapy in China
This study looks at how well patients with early-stage lung cancer (that has been surgically removed) do when treated with a targeted drug called EGFR-TKI to prevent cancer from coming back. Researchers will track actual patient outcomes in China from 2023 to 2026.
BeijingAges 18 years+ - NCT07589530RecruitingPhase 1/Phase 2
CAR NK Cell Therapy for Advanced Solid Tumors
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07590934RecruitingPhase 1/Phase 2
Drug combination study for advanced prostate cancer
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
Duarte, CaliforniaAges 18–99 - NCT07586202RecruitingPhase 2
Testing New Drug Combinations Before Lung Cancer Surgery
This trial tests whether giving new drugs (amivantamab plus either lazertinib or chemotherapy) before surgery helps people with a specific type of lung cancer that can be removed. The goal is to shrink tumors and improve surgery outcomes.
Duarte, CaliforniaAges 18 years+ - NCT07587866Recruiting
Panuri Test for Suspected Pancreatic Cancer
This study tests a new diagnostic tool called Panuri to help detect pancreatic cancer in adults who have symptoms suggesting the disease. The test may help doctors identify pancreatic cancer earlier and more accurately.
BékéscsabaAges 18 years+ - NCT07589634RecruitingPhase 2
Tocilizumab to prevent side effects from ramantamig in multiple myeloma
This study tests whether a drug called tocilizumab can prevent serious side effects (cytokine release syndrome) when combined with a new cancer drug called ramantamig. You'll be eligible if you have multiple myeloma that has come back or stopped responding to prior treatments.
Goodyear, ArizonaAges 18 years+ - NCT07591155RecruitingPhase 1
Testing BL-ARC002 for advanced solid tumors
This early-stage trial tests a new cancer drug called BL-ARC002 in patients whose advanced or spread cancers (solid tumors) have not responded to standard treatments. The drug is an antibody designed to help the immune system fight cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07586943RecruitingPhase 1/Phase 2
Study of SKB118 for advanced solid tumors
This study tests an experimental drug called SKB118 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07586618RecruitingPhase 1
New Drug 4A10 for Hard-to-Treat Lymphoblastic Leukemia or Lymphoma
This is an early-stage study testing a new experimental drug (4A10) in patients whose acute lymphoblastic leukemia or lymphoblastic lymphoma has returned or stopped responding to standard treatments. Researchers want to learn if the drug is safe and how it works in the body.
Aurora, ColoradoAges 18 years+ - NCT07589517RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Colorectal Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to fight advanced colorectal cancer that has spread or cannot be surgically removed. The therapy is customized to target specific protein markers on your cancer cells.
Shenzhen, GuangdongAges 18–75 - NCT07594106RecruitingPhase 1/Phase 2
New immunotherapy for advanced prostate or kidney cancer
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
Goodyear, ArizonaAges 18 years+ - NCT07591090RecruitingPhase 2
Drug combination study for advanced HER2-negative breast cancer
This study tests whether combining two new drugs (AK146D1 and AK112) can help people with advanced breast cancer that is HER2-negative (a type that doesn't have too much of a specific growth protein). The goal is to see if this combination can shrink tumors and improve survival.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07590531RecruitingPhase 1/Phase 2
Two-Drug Lung Cancer Treatment Study
This trial tests a combination of two experimental drugs (AMT-116 and ivosidan) for patients with advanced lung cancer that cannot be removed by surgery. The study aims to see if this combination can help shrink tumors and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT05655260Recruiting
Personalized treatment for high-risk endometrial cancer
This study tests a treatment plan tailored to your specific type of high-risk endometrial (uterine) cancer. It may help by matching therapy to your cancer features and overall health.
HelsinkiAges 18–100 - NCT06700395RecruitingPhase 1
Study of TQB2029 for multiple myeloma patients
This trial tests a new injectable drug, TQB2029, for people with multiple myeloma. It aims to see if the drug is safe and effective, and may be an option if you have measurable disease and are in relatively good health.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06148298Recruiting
Using a blood test to find pancreatic cancer
This study is testing a new blood test that looks for DNA changes to help find pancreatic cancer. It may lead to a way to find cancer earlier.
Orlando, FloridaAges 18 years+ - NCT07586891Recruiting
Low-Branched-Chain Amino Acid Diet With Immunotherapy for Stage III Melanoma
This trial tests whether a special diet low in certain amino acids (building blocks of protein), combined with an immune-boosting antibody drug, can safely shrink stage III melanoma that has spread to lymph nodes. The goal is to see if this combination works better than standard treatment.
Xi'anAges 18–75 - NCT07594925RecruitingPhase 2
Short-course radiation plus immunotherapy and chemotherapy for rectal cancer
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
TianjinAges 18–75 - NCT07594067RecruitingPhase 1
TCR T cells for KRAS-mutated cancers
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07587216Recruiting
Liver Cancer Patient Database Study
This study builds a database of information from liver cancer patients treated at Tongji Hospital. Researchers will collect your medical records and treatment information to better understand liver cancer diagnosis and care over time.
Wuhan, HubeiAges 18 years+ - NCT07586709RecruitingEarly Phase 1
CAR-T cell therapy targeting BCMA and GPRC5D for advanced plasma cell cancers
This trial is testing a new type of cell therapy that uses your own immune cells (called CAR-T cells) to fight your cancer. The cells are modified to attack two specific targets on your cancer cells (BCMA and GPRC5D) to potentially improve treatment response.
BeijingAges 18–75 - NCT07594015RecruitingPhase 2
Pembrolizumab and lenvatinib for recurrent endometrial cancer
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for women whose endometrial cancer has returned after initial treatment with immunotherapy. The goal is to see if this combination can help shrink or control the cancer.
Miami, FloridaAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,151 recruiting oncology studies from the U.S. registry right now, out of 30,040 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.